Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 07, 2024

Long-Term Outcomes of Neoadjuvant Dabrafenib and Trametinib in Patients With Stage III Melanoma

Annals of Oncology


Additional Info

Annals of Oncology
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma
Ann. Oncol 2024 May 14;[EPub Ahead of Print], AM Menzies, SN Lo, RPM Saw, M Gonzalez, S Ch'ng, OE Nieweg, KF Shannon, PM Ferguson, J Lee, L Emmett, R Kapoor, RV Rawson, JR Stretch, JF Thompson, AJ Spillane, H Rizos, RA Scolyer, GV Long

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading